<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040543</url>
  </required_header>
  <id_info>
    <org_study_id>1410234</org_study_id>
    <nct_id>NCT04040543</nct_id>
  </id_info>
  <brief_title>Development of a Marker of Adherence for Tracking Consumption of Nutrient Supplements</brief_title>
  <official_title>Development of a Biomarker to Assess Adherence to Nutrients Supplements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether selected adherence markers can be used to
      track daily or intermittent consumption of nutrient supplements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will assess whether urinary concentrations of selected adherence markers
      can be used to distinguish between daily or intermittent consumption of lipid-based nutrient
      supplements.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary concentration of saccharin (nmol/L)</measure>
    <time_frame>change in concentration between study day 4 (baseline) and study days 7,8,12,13 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary concentration of saccharin (nmol/g creatinine)</measure>
    <time_frame>change in concentration between study day 4 (baseline) and study days 7,8,12,13 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary concentration of resveratrol metabolites (nmol/L)</measure>
    <time_frame>change in concentration between study day 4 (baseline) and study days 7,8,12,13 and 15</time_frame>
    <description>resveratrol metabolites may include resveratrol glucuronides and/or resveratrol sulfates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary concentration of resveratrol metabolites (nmol/g creatnine)</measure>
    <time_frame>change in concentration between study day 4 (baseline) and study days 7,8,12,13 and 15</time_frame>
    <description>resveratrol metabolites may include resveratrol glucuronides and/or resveratrol sulfates</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adherence, Treatment</condition>
  <arm_group>
    <arm_group_label>Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily supplementation with product containing markers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily supplementation with either the product containing markers or the product not containing markers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily supplementation with product not containing markers</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lipid-based nutrient supplement containing adherence markers</intervention_name>
    <description>The supplement will be provided once daily for 10 days</description>
    <arm_group_label>Daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lipid-based nutrient supplement containing or not containing adherence markers</intervention_name>
    <description>The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.</description>
    <arm_group_label>Intermittent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lipid-based nutrient supplement not containing adherence markers</intervention_name>
    <description>The supplement will be provided once daily for 10 days</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-pregnant, non-lactating women

        Exclusion Criteria:

          -  BMI &lt;18.5kg/m2 or &gt;25.0 kg/m2

          -  Diagnosis of chronic disease

          -  Use of medication that can affect gastrointestinal mobility

          -  Consumption of more than 7 alcoholic drinks per week

          -  Smoking

          -  Unwillingness to refrain from consuming dietary sources of the marker compound(s) 3
             days prior to, and during the 12 day urine collection period

          -  Unwillingness to adhere to the study protocol

          -  Peanut allergy

          -  Cow milk allergy

          -  Soy allergy

          -  Almond allergy

          -  Allergy to adherence markers

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjorie Haskell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nutrients</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

